Promising reductions in rate of VOCs/SCPCs observed in monotherapy IMR-687 treated patients vs. placebo

Read the rest here:
Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *